Alkem Laboratories shares fell nearly 4% following Q4 earnings. While revenue and profit rose 4% year-over-year, the results missed expectations from multiple brokerages, citing weak growth in key markets and concerns about future margins.

• Q4 revenue growth underperformed forecasts.
• Increased R&D will pressure margins.
• Limited catalysts expected for FY25-27.